BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

Terms: = Ovarian cancer AND ERBB2, c-erb B2, 2064, P04626, ENSG00000141736, c-erbB2, HER-2/neu, HER2, TKR1, NEU, NGL, HER-2
1813 results:

  • 1. The Predictive Role of Serum Lipid Levels, p53 and ki-67, According to Molecular Subtypes in Breast cancer: A Randomized Clinical Study.
    Faur IF; Dobrescu A; Clim IA; Pasca P; Prodan-Barbulescu C; Tarta C; Neamtu AA; Brebu D; Neamtu C; Rosu M; Duta C; Clim A; Lazar G; Totolici B
    Int J Mol Sci; 2024 Mar; 25(7):. PubMed ID: 38612725
    [TBL] [Abstract] [Full Text] [Related]  

  • 2. Human epidermal growth factor receptor-2 expression and subsequent dynamic changes in patients with ovarian cancer.
    Kim YN; Chung YS; Park E; Lee ST; Lee JY
    Sci Rep; 2024 Apr; 14(1):7992. PubMed ID: 38580676
    [TBL] [Abstract] [Full Text] [Related]  

  • 3. Bispecific immune cell engager enhances the anticancer activity of CD16+ NK cells and macrophages in vitro, and eliminates cancer metastasis in NK humanized NOG mice.
    Khoshtinat Nikkhoi S; Yang G; Owji H; Grizotte-Lake M; Cohen RI; Gil Gonzalez L; Massumi M; Hatefi A
    J Immunother Cancer; 2024 Mar; 12(3):. PubMed ID: 38490714
    [TBL] [Abstract] [Full Text] [Related]  

  • 4. her2-low and Overexpression in Mucinous ovarian cancer: Analysis of ASCO/CAP and ToGA Immunohistochemical Scoring.
    Han R; Madariaga A; Gonzalez-Ochoa E; Smith AC; Wang L; Lheureux S; Rouzbahman M
    Int J Gynecol Pathol; 2024 May; 43(3):275-283. PubMed ID: 38436360
    [TBL] [Abstract] [Full Text] [Related]  

  • 5. Combined inhibition of her2 and VEGFR synergistically improves therapeutic efficacy via PI3K-AKT pathway in advanced ovarian cancer.
    Li W; Zhang K; Wang W; Liu Y; Huang J; Zheng M; Li L; Zhang X; Xu M; Chen G; Wang L; Zhang S
    J Exp Clin Cancer Res; 2024 Feb; 43(1):56. PubMed ID: 38403634
    [TBL] [Abstract] [Full Text] [Related]  

  • 6. Trichorhinophalangeal Syndrome Type 1 Immunohistochemical Expression in Carcinomas of Gynecologic Origin.
    Ruiz F; Tjendra Y; Millan N; Gomez-Fernandez C; Pinto A
    Am J Surg Pathol; 2024 May; 48(5):546-550. PubMed ID: 38357982
    [TBL] [Abstract] [Full Text] [Related]  

  • 7. Clinicopathological pattern of oestrogen receptor, progesterone receptor and human epidermal growth factor receptor-2 over-expression of epithelial ovarian carcinomas in Nigeria.
    Ajani MA; Lawan A; Oke T; Khramtsova G; Nwanji I; Salami A; Awolude O; Ebili H; Onwukamuche ME; Sveen E; Yoshimatsu T; Olopade OI
    Afr Health Sci; 2023 Sep; 23(3):236-244. PubMed ID: 38357171
    [TBL] [Abstract] [Full Text] [Related]  

  • 8. Somatic Genomic and Transcriptomic Characterization of Primary ovarian Serous Borderline Tumors and Low-Grade Serous Carcinomas.
    Stružinská I; Hájková N; Hojný J; Krkavcová E; Michálková R; Bui QH; Matěj R; Laco J; Drozenová J; Fabian P; Škapa P; Špůrková Z; Cibula D; Frühauf F; Jirásek T; Zima T; Méhes G; Kendall Bártů M; Němejcová K; Dundr P
    J Mol Diagn; 2024 Apr; 26(4):257-266. PubMed ID: 38280423
    [TBL] [Abstract] [Full Text] [Related]  

  • 9.
    Bao S; Sun N; Li Y; Shu J; Xu J; Zhang Y; Qiu X
    J Int Med Res; 2024 Jan; 52(1):3000605231223426. PubMed ID: 38263931
    [TBL] [Abstract] [Full Text] [Related]  

  • 10. PARP Inhibitors in Breast cancer: a Short Communication.
    Daly GR; AlRawashdeh MM; McGrath J; Dowling GP; Cox L; Naidoo S; Vareslija D; Hill ADK; Young L
    Curr Oncol Rep; 2024 Feb; 26(2):103-113. PubMed ID: 38236558
    [TBL] [Abstract] [Full Text] [Related]  

  • 11. Predictive and prognostic biomarkers in female genital tract tumours: an update highlighting their clinical relevance and practical issues.
    Wong RW; Cheung ANY
    Pathology; 2024 Mar; 56(2):214-227. PubMed ID: 38212229
    [TBL] [Abstract] [Full Text] [Related]  

  • 12. Systemic Treatment of Patients With Metastatic Breast cancer: ASCO Resource-Stratified Guideline.
    Al Sukhun S; Temin S; Barrios CH; Antone NZ; Guerra YC; Chavez-MacGregor M; Chopra R; Danso MA; Gomez HL; Homian NM; Kandil A; Kithaka B; Koczwara B; Moy B; Nakigudde G; Petracci FE; Rugo HS; El Saghir NS; Arun BK
    JCO Glob Oncol; 2024 Jan; 10():e2300285. PubMed ID: 38206277
    [TBL] [Abstract] [Full Text] [Related]  

  • 13. Pan-EGFR Inhibitor Dacomitinib Resensitizes Paclitaxel and Induces Apoptosis via Elevating Intracellular ROS Levels in ovarian cancer SKOV3-TR Cells.
    Lim YJ; Kim HS; Bae S; So KA; Kim TJ; Lee JH
    Molecules; 2024 Jan; 29(1):. PubMed ID: 38202856
    [TBL] [Abstract] [Full Text] [Related]  

  • 14. Prognostic factors and benefit populations of ovarian function suppression in premenopausal HR+/her2+ early-stage breast cancer patients who received trastuzumab: Evidence from a real-world study with long-term follow-up.
    Ju J; Gao SL; Wang JY; Sang D; Kang YK; Wang X; Yue J; Shuai Y; Qi YX; Yuan P
    Thorac Cancer; 2024 Feb; 15(6):439-447. PubMed ID: 38185807
    [TBL] [Abstract] [Full Text] [Related]  

  • 15. Antibody-Drug Conjugates in Gynecologic cancers.
    Anastasio MK; Shuey S; Davidson BA
    Curr Treat Options Oncol; 2024 Jan; 25(1):1-19. PubMed ID: 38172449
    [TBL] [Abstract] [Full Text] [Related]  

  • 16. Multifactor assessment of ovarian cancer reveals immunologically interpretable molecular subtypes with distinct prognoses.
    Guo Y; Li S; Li C; Wang L; Ning W
    Front Immunol; 2023; 14():1326018. PubMed ID: 38143770
    [TBL] [Abstract] [Full Text] [Related]  

  • 17. Learning Outcomes of "GetSMART," Education for Diagnostics and Targeted Treatment for her2+ Metastatic Gastric and Colorectal cancers.
    Augustyniak M; Lou E; Jacobs G; Fleming M; Marshall J; Coutinho A; Yoshino T
    J Cancer Educ; 2024 Apr; 39(2):118-125. PubMed ID: 38135836
    [TBL] [Abstract] [Full Text] [Related]  

  • 18. Radiolabelled
    Cieslik PA; Klingler S; Nolff M; Holland JP
    Chemistry; 2024 Mar; 30(14):e202303805. PubMed ID: 38064536
    [TBL] [Abstract] [Full Text] [Related]  

  • 19. Hybrid Membrane Camouflaged Chemodrug-Gene Nanoparticles for Enhanced Combination Therapy of ovarian cancer.
    Chen T; Wang Y; Zhu L; Wu J; Lin J; Huang W; Yan D
    ACS Appl Mater Interfaces; 2023 Dec; 15(50):58067-58078. PubMed ID: 38056905
    [TBL] [Abstract] [Full Text] [Related]  

  • 20. Molecular landscape of erbb2/her2 gene amplification among patients with gynecologic malignancies; clinical implications and future directions.
    Nasioudis D; Gysler S; Latif N; Cory L; Giuntoli RL; Kim SH; Simpkins F; Martin L; Ko EM
    Gynecol Oncol; 2024 Jan; 180():1-5. PubMed ID: 38029652
    [TBL] [Abstract] [Full Text] [Related]  


    [Next]

    of 91.